Radiation Therapist Vacancy Rates on the Decline, New Data Reveal

Why It Matters

Reduced vacancies signal that recruitment and pipeline initiatives are beginning to work, helping hospitals maintain treatment capacity and control costs. A steadier staffing picture improves patient access to timely radiation therapy, a critical component of cancer care.

Key Takeaways

• Radiation therapist vacancy fell from 13.6% to 11.4% (2025‑26).
• Dosimetrist openings dropped from 9.6% to 6.8% (2025‑26).
• FTE therapist vacancies per facility declined to 8.1 from 8.3.
• Survey included 560 respondents, 2.4% response, ±4.1% error margin.

Pulse Analysis

The radiation‑therapy sector has grappled with chronic staffing shortages since 2018, when vacancy rates began climbing sharply. High turnover and limited training slots forced many oncology centers to delay treatments, inflating costs and compromising patient outcomes. The latest ASRT survey, covering 560 facilities, reveals a modest but meaningful reversal: therapist vacancies slipped to 11.4% and dosimetrist gaps to 6.8%, suggesting the market is moving toward equilibrium.

ASRT attributes the improvement to targeted workforce programs. Dedicated work groups have partnered with academic institutions, expanded scholarship funds, and launched mentorship pathways to attract new talent. By promoting the specialty through outreach and streamlined certification processes, the organization is widening the pipeline of qualified candidates. These efforts not only replenish the talent pool but also elevate the profession’s visibility, encouraging more technologists to specialize in radiation therapy.

Looking ahead, hospitals must translate these gains into sustainable staffing models. While vacancy rates are declining, the modest response rate and ±4.1% margin of error caution against complacency. Continued investment in training, competitive compensation, and retention incentives will be essential to prevent a resurgence of shortages. For health systems, stabilizing the radiation‑therapy workforce translates to steadier operational costs, improved patient throughput, and stronger positioning in the competitive oncology market.